Robert K. Zeldin

Robert K. Zeldin

Chief Medical Officer

  • With Ablynx since 2015
  • Previously: Merck & Co., Inc. and Novartis Pharmaceuticals Corp. 

Robert joined Ablynx in December 2015 as Chief Medical Officer. He leads the Company’s global clinical development, regulatory and medical affairs activities. 

Robert brings significant industry experience to the Company, having held senior level clinical development positions at top tier pharmaceutical companies. In his previous roles, he headed teams in immunology, respiratory, dermatology and cardiovascular disease where he was responsible for clinical development through to commercialisation and life cycle management. He also successfully engaged key stakeholders including the scientific community, payers, patient advocacy groups and key opinion leaders. 

Prior to his move into the pharmaceutical industry, Robert spent several years in private practice and two years as a Medical Officer at the FDA’s Center for Biologics Evaluation and Research. There he evaluated safety and efficacy data from all phases of clinical development. He holds a Medical Doctor degree from the Tufts University School of Medicine, Boston, USA. He completed Internship and Residency in Internal Medicine at the University Health Center of Pittsburgh and Fellowship in Allergy & Clinical Immunology at the Johns Hopkins University School of Medicine.


< Back